KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Cash & Current Investments: 2009-2024

Historic Cash & Current Investments for Halozyme Therapeutics (HALO) over the last 16 years, with Dec 2024 value amounting to $596.1 million.

  • Halozyme Therapeutics' Cash & Current Investments rose 5.35% to $702.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 billion, marking a year-over-year increase of 30.05%. This contributed to the annual value of $596.1 million for FY2024, which is 77.40% up from last year.
  • Halozyme Therapeutics' Cash & Current Investments amounted to $596.1 million in FY2024, which was up 77.40% from $336.0 million recorded in FY2023.
  • Over the past 5 years, Halozyme Therapeutics' Cash & Current Investments peaked at $740.9 million during FY2021, and registered a low of $336.0 million during FY2023.
  • Moreover, its 3-year median value for Cash & Current Investments was $362.8 million (2022), whereas its average is $431.6 million.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first soared by 101.33% in 2021, then crashed by 51.03% in 2022.
  • Over the past 5 years, Halozyme Therapeutics' Cash & Current Investments (Yearly) stood at $368.0 million in 2020, then spiked by 101.33% to $740.9 million in 2021, then slumped by 51.03% to $362.8 million in 2022, then decreased by 7.39% to $336.0 million in 2023, then surged by 77.40% to $596.1 million in 2024.